Is chymase 1 a therapeutic target in cardiovascular disease?

References

• Zhou B, Carrillo-Larco RM, Danaei G, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957–980. 2021/09/11/. doi: 10.1016/S0140-6736(21)01330-1
   PubMed Web of Science ®Google Scholar
• Khalil H, Zeltser R. Antihypertensive Medications. StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
   Google Scholar
• Coca A, Kreutz R, Manolis AJ, et al. A practical approach to switch from a multiple pill therapeutic strategy to a polypill-based strategy for cardiovascular prevention in patients with hypertension. J Hypertens. 2020 Oct;38(10):1890–1898. doi: 10.1097/HJH.0000000000002464
   PubMed Web of Science ®Google Scholar
• Joseph P, Roshandel G, Gao P, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet. 2021 Sep 25;398(10306):1133–1146. doi: 10.1016/S0140-6736(21)01827-4
   PubMed Web of Science ®Google Scholar
• Aitken M, Kleinrock M, Pritchett J. The use of medicines in the U.S.: usage and spending trends and outlook to 2026. IQVIA Institute for Human Data Science; 2022. p. 64. https://www.iqvia.com/insights/the-iqvia-institute/reports/the-use-of-medicines-in-the-us
   Google Scholar
• Williams B, Mancia G. Ten Commandments of the 2018 ESC/ESH HTN guidelines on hypertension in adults. Eur Heart J. 2018 Sep 1;39(33):3007–3008. doi: 10.1093/eurheartj/ehy439
   PubMed Web of Science ®Google Scholar
• Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008 Jan 1;148(1):16–29. doi: 10.7326/0003-4819-148-1-200801010-00189
   PubMed Web of Science ®Google Scholar
• Sanders GD, Powers B, Crowley M, et al. Future research needs for angiotensin converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease. In: Identification of future research need. agency for healthcare research and quality. U.S. Department of Health and Human Services, 2010. AHRQ; 2010.
   Google Scholar
• Ferrario CM, Saha A, VonCannon JL, et al. Does the naked emperor parable apply to current perceptions of the Contribution of renin angiotensin system inhibition in hypertension? Curr Hypertens Rep. 2022 Dec;24(12):709–721. doi: 10.1007/s11906-022-01229-x
   PubMed Web of Science ®Google Scholar
• Chen R, Suchard MA, Krumholz HM, et al. Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study. Hypertension. 2021 Sep;78(3):591–603. doi: 10.1161/HYPERTENSIONAHA.120.16667
   PubMed Web of Science ®Google Scholar
• Reyes S, Varagic J, Ahmad S, et al. Novel cardiac intracrine mechanisms based on Ang-(1-12)/Chymase axis require a revision of therapeutic approaches in human heart disease. Curr Hypertens Rep. 2017 Feb;19(2):16. doi: 10.1007/s11906-017-0708-3
   PubMed Web of Science ®Google Scholar
• Vanuzzo D. The epidemiological concept of residual risk. Intern Emerg Med. 2011 Oct;6(Suppl 1):45–51. doi: 10.1007/s11739-011-0669-5
   PubMedGoogle Scholar
• Turnbull F, Neal B, Blood Pressure Lowering Treatment Trialists C, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ.2008 May 17;336(7653):1121–1123.
   PubMedGoogle Scholar
• Turnbull F, Neal B, Algert C, et al. Blood Pressure Lowering Treatment Trialists C. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165(12):1410–9. doi: 10.1001/archinte.165.12.1410
   PubMedGoogle Scholar
• Dusing R, Sellers F. ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. Curr Med Res Opin. 2009 Sep;25(9):2287–2301. doi: 10.1185/03007990903152045
   PubMed Web of Science ®Google Scholar
• Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019 Dec;25(12):1822–1832. doi: 10.1038/s41591-019-0675-0
   PubMed Web of Science ®Google Scholar
• Ferrario CM, Ahmad S, Varagic J, et al. Intracrine angiotensin II functions originate from noncanonical pathways in the human heart. Am J Physiol Heart Circ Physiol. 2016 Aug 1;311(2):H404–14. doi: 10.1152/ajpheart.00219.2016
   PubMed Web of Science ®Google Scholar
• Abadir PM, Walston JD, Carey RM. Subcellular characteristics of functional intracellular renin-angiotensin systems. Peptides. 2012 Dec;38(2):437–445. doi: 10.1016/j.peptides.2012.09.016
   PubMed Web of Science ®Google Scholar
• Kumar R, Singh VP, Baker KM. The intracellular renin-angiotensin system: implications in cardiovascular remodeling. Curr Opin Nephrol Hypertens. 2008 Mar;17(2):168–173. doi: 10.1097/MNH.0b013e3282f521a8
   PubMed Web of Science ®Google Scholar
• Re RN. Mechanisms of disease: local renin-angiotensin-aldosterone systems and the pathogenesis and treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2004 Nov;1(1):42–47. doi: 10.1038/ncpcardio0012
   PubMedGoogle Scholar
• Abassi Z, Skorecki K, Hamo-Giladi DB, et al. Kinins and chymase: the forgotten components of the renin-angiotensin system and their implications in COVID-19 disease. Am J Physiol Lung Cell Mol Physiol. 2021 Mar 1;320(3):L422–L429. doi: 10.1152/ajplung.00548.2020
   PubMed Web of Science ®Google Scholar
• Ahmad S, Ferrario CM. Chymase inhibitors for the treatment of cardiac diseases: a patent review (2010-2018). Expert Opin Ther Pat. 2018 Nov;28(11):755–764. doi: 10.1080/13543776.2018.1531848
   PubMed Web of Science ®Google Scholar
• Ondetti MA, Cushman DW. Enzymes of the renin-angiotensin system and their inhibitors. Annu Rev Biochem. 1982;51(1):283–308. doi: 10.1146/annurev.bi.51.070182.001435
   PubMedGoogle Scholar
• Skeggs LT, Dorer FE, Kahn JR, et al. The biological production of angiotensin. In: Page I Bumpus Feditors. Angiotensin handbook of experimental pharmacologyVol. XXXVII. XXXVII Springer-Verlag: Berlin -Heidelberg - (NY); 1974. p. 1–7. 10.1007/978-3-642-65600-2_1
   Google Scholar
• Santos RA, Brosnihan KB, Chappell MC, et al. Converting enzyme activity and angiotensin metabolism in the dog brainstem. Hypertension. 1988 Feb;11(2 Pt 2):I153–7. doi: 10.1161/01.HYP.11.2_Pt_2.I153
   PubMed Web of Science ®Google Scholar
• Schiavone MT, Santos RA, Brosnihan KB, et al. Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide. Proc Natl Acad Sci U S A. 1988 Jun;85(11):4095–4098. doi: 10.1073/pnas.85.11.4095
   PubMed Web of Science ®Google Scholar
• Benter IF, Diz DI, Ferrario CM. Cardiovascular actions of angiotensin(1-7). Peptides. 1993 Jul;14(4):679–684. doi: 10.1016/0196-9781(93)90097-Z
   PubMed Web of Science ®Google Scholar
• Ferrario CM. Contribution of angiotensin-(1-7) to cardiovascular physiology and pathology. Curr Hypertens Rep. 2003 Apr;5(2):129–134. doi: 10.1007/s11906-003-0069-y
   PubMed Web of Science ®Google Scholar
• Tikellis C, Thomas MC. Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in Health and disease. Int J Pept. 2012;2012:256294. doi: 10.1155/2012/256294
   PubMedGoogle Scholar
• Turner AJ, Tipnis SR, Guy JL, et al. ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors. Can J Physiol Pharmacol. 2002 Apr;80(4):346–353. doi: 10.1139/y02-021
   PubMed Web of Science ®Google Scholar
• Rice GI, Thomas DA, Grant PJ, et al. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J. 2004 Oct 1;383(Pt 1):45–51. doi: 10.1042/BJ20040634
   PubMedGoogle Scholar
• Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002 Apr 26;277(17):14838–14843. doi: 10.1074/jbc.M200581200
   PubMed Web of Science ®Google Scholar
• Jankowski V, Vanholder R, van der Giet M, et al. Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol. 2007 Feb;27(2):297–302. doi: 10.1161/01.ATV.0000253889.09765.5f
   PubMed Web of Science ®Google Scholar
• Lautner RQ, Villela DC, Fraga-Silva RA, et al. Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ Res. 2013 Apr 12;112(8):1104–1111. doi: 10.1161/CIRCRESAHA.113.301077
   PubMed Web of Science ®Google Scholar
• Ferrario CM, Groban L, Wang H, et al. The renin-angiotensin system biomolecular cascade: a 2022 update of newer insights and concepts. Kidney Int Suppl. 2022 Apr;12(1):36–47. doi: 10.1016/j.kisu.2021.11.002
   Web of Science ®Google Scholar
• Hrenak J, Paulis L, Simko F. Angiotensin A/Alamandine/MrgD axis: another clue to understanding cardiovascular pathophysiology. Int J Mol Sci. 2016 Jul 20;17(7):1098. doi: 10.3390/ijms17071098
   PubMed Web of Science ®Google Scholar
• Nagata S, Kato J, Sasaki K, et al. Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system. Biochem Biophys Res Commun. 2006 Dec 1;350(4):1026–1031. doi: 10.1016/j.bbrc.2006.09.146
   PubMed Web of Science ®Google Scholar
• Husain A, Bumpus FM, Smeby RR, et al. Evidence for the existence of a family of biologically active angiotensin I-like peptides in the dog central nervous system. Circ Res. 1983 Apr;52(4):460–464. doi: 10.1161/01.RES.52.4.460
   PubMed Web of Science ®Google Scholar
• Bumpus FM, Catt KJ, Chiu AT, et al. Nomenclature for angiotensin receptors. A report of the Nomenclature committee of the council for high blood pressure research. Hypertension. 1991;17(5):720–721. doi: 10.1161/01.HYP.17.5.720
   PubMed Web of Science ®Google Scholar
• Moniwa N, Varagic J, Simington SW, et al. Primacy of angiotensin converting enzyme in angiotensin-(1-12) metabolism. Am J Physiol Heart Circ Physiol. 2013 Sep 1;305(5):H644–50. doi: 10.1152/ajpheart.00210.2013
   PubMed Web of Science ®Google Scholar
• Ahmad S, Simmons T, Varagic J, et al. Chymase-dependent generation of angiotensin II from angiotensin-(1-12) in human atrial tissue. PLoS One. 2011;6(12):e28501. doi: 10.1371/journal.pone.0028501
   PubMed Web of Science ®Google Scholar
• Ahmad S, Varagic J, Groban L, et al. Angiotensin-(1-12): a chymase-mediated cellular angiotensin II substrate. Curr Hypertens Rep. 2014 May;16(5):429. doi: 10.1007/s11906-014-0429-9
   PubMed Web of Science ®Google Scholar
• Ahmad S, Varagic J, VonCannon JL, et al. Primacy of cardiac chymase over angiotensin converting enzyme as an angiotensin-(1-12) metabolizing enzyme. Biochem Biophys Res Commun. 2016 Sep 16;478(2):559–564. doi: 10.1016/j.bbrc.2016.07.100
   PubMed Web of Science ®Google Scholar
• Ahmad S, Wei CC, Tallaj J, et al. Chymase mediates angiotensin-(1-12) metabolism in normal human hearts. J Am Soc Hypertens. 2013 Mar;7(2):128–136. doi: 10.1016/j.jash.2012.12.003
   PubMed Web of Science ®Google Scholar
• Ahmad S, Wright KN, Ferrario CM, et al. Internalization of angiotensin-(1-12) in adult retinal pigment epithelial-19 cells. FASEB J. 2022;36(S1): doi: 10.1096/fasebj.2022.36.S1.L7802
   Google Scholar
• Trask AJ, Jessup JA, Chappell MC, et al. Angiotensin-(1-12) is an alternate substrate for angiotensin peptide production in the heart. Am J Physiol Heart Circ Physiol. 2008 May;294(5):H2242–7. doi: 10.1152/ajpheart.00175.2008
   PubMed Web of Science ®Google Scholar
• Westwood BM, Chappell MC. Divergent pathways for the angiotensin-(1-12) metabolism in the rat circulation and kidney. Peptides. 2012 Jun;35(2):190–195. doi: 10.1016/j.peptides.2012.03.025
   PubMed Web of Science ®Google Scholar
• Yamashita T, Ahmad S, Wright KN, et al. Noncanonical mechanisms for direct bone marrow generating Ang II (angiotensin II) predominate in CD68 positive myeloid lineage cells. Hypertension. 2020 Feb;75(2):500–509. doi: 10.1161/HYPERTENSIONAHA.119.13754
   PubMed Web of Science ®Google Scholar
• Simington SW, Moniwa N, Ahmad S, et al. Renin does not participate in the production of plasma Ang-(1–12) from angiotensinogen. Hypertension. 2013;60(suppl_1):A628. doi: 10.1161/hyp.60.suppl_1.A628
   Google Scholar
• Simington SW, Moniwa N, Ahmad S, et al. Abstract 628: Renin does not participate in the production of plasma Ang-(1-12) from angiotensinogen. Hypertension. 2012;60(suppl_1):A628–A628. doi: 10.1161/hyp.60.suppl_1.A628
   Google Scholar
• Ahmad S, Varagic J, Westwood BM, et al. Uptake and metabolism of the novel peptide angiotensin-(1-12) by neonatal cardiac myocytes. PLoS One. 2011 Jan 10;6(1):e15759. doi: 10.1371/journal.pone.0015759
   PubMed Web of Science ®Google Scholar
• De Mello WC, Dell’itallia LJ, Varagic J, et al. Intracellular angiotensin-(1-12) changes the electrical properties of intact cardiac muscle. Mol Cell Biochem. 2016 Nov;422(1–2):31–40. doi: 10.1007/s11010-016-2801-3
   PubMed Web of Science ®Google Scholar
• Reyes S, Cheng CP, Roberts DJ, et al. Angiotensin-(1-12)/chymase axis modulates cardiomyocyte L-type calcium currents in rats expressing human angiotensinogen. Int J Cardiol. 2019 Dec 15;297:104–110. doi: 10.1016/j.ijcard.2019.09.052
   PubMed Web of Science ®Google Scholar
• Ferrario CM, VonCannon J, Ahmad S, et al. Activation of the human angiotensin-(1-12)-chymase pathway in rats with human angiotensinogen gene transcripts. Front Cardiovasc Med. 2019;6:163. DOI:10.3389/fcvm.2019.00163
   PubMed Web of Science ®Google Scholar
• Pulgar VM, Cruz-Diaz N, Westwood BM, et al. Angiotensinogen uptake and stimulation of oxidative stress in human pigment retinal epithelial cells. Peptides. 2022 Feb 18;152:170770. doi: 10.1016/j.peptides.2022.170770
   PubMed Web of Science ®Google Scholar
• Li T, Zhang X, Cheng HJ, et al. Critical role of the chymase/angiotensin-(1-12) axis in modulating cardiomyocyte contractility. Int J Cardiol. 2018 Aug 1;264:137–144. doi: 10.1016/j.ijcard.2018.03.066
   PubMed Web of Science ®Google Scholar
• Urata H, Healy B, Stewart RW, et al. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res. 1990 Apr;66(4):883–890. doi: 10.1161/01.RES.66.4.883
   PubMed Web of Science ®Google Scholar
• Urata H, Kinoshita A, Misono KS, et al. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem. 1990 Dec 25;265(36):22348–22357. doi: 10.1016/S0021-9258(18)45712-2
   PubMed Web of Science ®Google Scholar
• Park S, Bivona BJ, Kobori H, et al. Major role for ACE-independent intrarenal ANG II formation in type II diabetes. Am J Physiol Renal Physiol. 2010 Jan;298(1):F37–48. doi: 10.1152/ajprenal.00519.2009
   PubMed Web of Science ®Google Scholar
• Lorenz JN. Chymase: the other ACE? Am J Physiol Renal Physiol. 2010 Jan;298(1):F35–6. doi: 10.1152/ajprenal.00641.2009
   PubMed Web of Science ®Google Scholar
• Kaltenecker CC, Domenig O, Kopecky C, et al. Critical role of neprilysin in kidney angiotensin metabolism. Circ Res. 2020 Aug 14;127(5):593–606. doi: 10.1161/CIRCRESAHA.119.316151
   PubMed Web of Science ®Google Scholar
• Pavo N, Prausmuller S, Spinka G, et al. Myocardial angiotensin metabolism in end-stage heart failure. J Am Coll Cardiol. 2021 Apr 13;77(14):1731–1743. doi: 10.1016/j.jacc.2021.01.052
   PubMed Web of Science ®Google Scholar
• Ferrario CM, Santos RA, Brosnihan KB, et al. A hypothesis regarding the function of angiotensin peptides in the brain. Clin Exp Hypertens A. 1988;10 Suppl 1(sup1):107–121. doi: 10.3109/10641968809075966
   PubMedGoogle Scholar
• Jessup JA, Trask AJ, Chappell MC, et al. Localization of the novel angiotensin peptide, angiotensin-(1-12), in heart and kidney of hypertensive and normotensive rats. Am J Physiol Heart Circ Physiol. 2008 Jun;294(6):H2614–8. doi: 10.1152/ajpheart.91521.2007
   PubMed Web of Science ®Google Scholar
• Ferrario CM, VonCannon J, Jiao Y, et al. Cardiac angiotensin-(1-12) expression and systemic hypertension in rats expressing the human angiotensinogen gene. Am J Physiol Heart Circ Physiol. 2016 Apr 15;310(8):H995–1002. doi: 10.1152/ajpheart.00833.2015
   PubMed Web of Science ®Google Scholar
• Balcells E, Meng QC, Johnson WH Jr., et al. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol. 1997 Oct;273(4):H1769–74. doi: 10.1152/ajpheart.1997.273.4.H1769
   PubMedGoogle Scholar
• Dell’italia LJ, Collawn JF, Ferrario CM. Multifunctional role of chymase in acute and chronic tissue injury and remodeling. Circ Res. 2018 Jan 19;122(2):319–336. doi: 10.1161/CIRCRESAHA.117.310978
   PubMed Web of Science ®Google Scholar
• Schechter I, Berger A. On the size of the active site in proteases. I Papain Biochem Biophys Res Commun. 1967 Apr 20;27(2):157–162. doi: 10.1016/S0006-291X(67)80055-X
   PubMed Web of Science ®Google Scholar
• Dell’italia LJ, Husain A. Dissecting the role of chymase in angiotensin II formation and heart and blood vessel diseases. Curr Opin Cardiol. 2002 Jul;17(4):374–379. doi: 10.1097/00001573-200207000-00009
   PubMed Web of Science ®Google Scholar
• Doggrell SA, Wanstall JC. Vascular chymase: pathophysiological role and therapeutic potential of inhibition. Cardiovasc Res. 2004;61(4):653–662. doi: 10.1016/j.cardiores.2003.11.029
   PubMed Web of Science ®Google Scholar
• Berglund P, Akula S, Fu Z, et al. Extended cleavage Specificity of the rat vascular chymase, a potential blood pressure regulating enzyme expressed by rat vascular smooth muscle cells. Int J Mol Sci. 2020 Nov 12;21(22):8546. doi: 10.3390/ijms21228546
   PubMed Web of Science ®Google Scholar
• Chandrasekharan UM, Sanker S, Glynias MJ, et al. Angiotensin II-forming activity in a reconstructed ancestral chymase. Science. 1996 Jan 26;271(5248):502–505. doi: 10.1126/science.271.5248.502
   PubMed Web of Science ®Google Scholar
• Lutzelschwab C, Pejler G, Aveskogh M, et al. Secretory granule proteases in rat mast cells. Cloning of 10 different serine proteases and a carboxypeptidase a from various rat mast cell populations. J Exp Med. 1997 Jan 6;185(1):13–29. doi: 10.1084/jem.185.1.13
   PubMed Web of Science ®Google Scholar
• Kunori Y, Koizumi M, Masegi T, et al. Rodent alpha-chymases are elastase-like proteases. Eur J Biochem. 2002 Dec;269(23):5921–5930. doi: 10.1046/j.1432-1033.2002.03316.x
   PubMedGoogle Scholar
• Caughey GH. Mast cell proteases as pharmacological targets. Eur J Pharmacol. 2016 May 5;778:44–55. doi: 10.1016/j.ejphar.2015.04.045
   PubMed Web of Science ®Google Scholar
• Guo C, Ju H, Leung D, et al. A novel vascular smooth muscle chymase is upregulated in hypertensive rats. J Clin Invest. 2001 Mar;107(6):703–715. doi: 10.1172/JCI9997
   PubMed Web of Science ®Google Scholar
• Kishi K, Jin D, Takai S, et al. Role of chymase-dependent angiotensin II formation in monocrotaline-induced pulmonary hypertensive rats. Pediatr Res. 2006 Jul;60(1):77–82. doi: 10.1203/01.pdr.0000219431.45075.d9
   PubMed Web of Science ®Google Scholar
• Wintroub BU, Schechter NB, Lazarus GS, et al. Angiotensin I conversion by human and rat chymotryptic proteinases. J Invest Dermatol. 1984 Nov;83(5):336–339. doi: 10.1111/1523-1747.ep12264144
   PubMed Web of Science ®Google Scholar
• Pejler G. Novel insight into the in vivo function of mast cell chymase: lessons from knockouts and inhibitors. J Innate Immun. 2020;12(5):357–372. doi: 10.1159/000506985
   PubMed Web of Science ®Google Scholar
• Wasse H, Naqvi N, Husain A. Impact of mast cell chymase on renal disease progression. Curr Hypertens Rev. 2012 Feb 1;8(1):15–23. doi: 10.2174/157340212800505007
   PubMedGoogle Scholar
• Rawlings ND, Barrett AJ, Thomas PD, et al. The MEROPS database of proteolytic enzymes, their substrates and inhibitors in 2017 and a comparison with peptidases in the PANTHER database. Nucleic Acids Res. 2018 Jan 4;46(D1):D624–d632. doi: 10.1093/nar/gkx1134
   PubMed Web of Science ®Google Scholar
• Fritz H. Human mucus proteinase inhibitor (human MPI). Human seminal inhibitor I (HUSI-I), antileukoprotease (ALP), secretory leukocyte protease inhibitor (SLPI). Biol Chem Hoppe-Seyler. 1988 May;369:79–82.
   PubMed Web of Science ®Google Scholar
• Schick C, Kamachi Y, Bartuski AJ, et al. Squamous cell carcinoma antigen 2 is a novel serpin that inhibits the chymotrypsin-like proteinases cathepsin G and mast cell chymase. J Biol Chem. 1997 Jan 17;272(3):1849–1855. doi: 10.1074/jbc.272.3.1849
   PubMed Web of Science ®Google Scholar
• Tinel H, Zubov D, Zimmermann K, et al. Abstract 13624: a novel chymase inhibitor BAY 1142524 reduces fibrosis and improves cardiac function after myocardial infarction in hamster. Circulation. 2017;136(suppl_1):A13624–A13624.
   Google Scholar
• Trivedi NN, Caughey GH. Mast cell peptidases: chameleons of innate immunity and host defense. Am J Respir Cell Mol Biol. 2010 Mar;42(3):257–267. doi: 10.1165/rcmb.2009-0324RT
   PubMed Web of Science ®Google Scholar
• Matsumoto C, Hayashi T, Kitada K, et al. Chymase plays an important role in left ventricular remodeling induced by intermittent hypoxia in mice. Hypertension. 2009 Jul;54(1):164–171. doi: 10.1161/HYPERTENSIONAHA.109.131391
   PubMed Web of Science ®Google Scholar
• Ishida K, Takai S, Murano M, et al. Role of chymase-dependent matrix metalloproteinase-9 activation in mice with dextran sodium sulfate-induced colitis. J Pharmacol Exp Ther. 2008 Feb;324(2):422–426. doi: 10.1124/jpet.107.131946
   PubMed Web of Science ®Google Scholar
• Inoue N, Muramatsu M, Jin D, et al. Effects of chymase inhibitor on angiotensin II-induced abdominal aortic aneurysm development in apolipoprotein E-deficient mice. Atherosclerosis. 2009 Jun;204(2):359–364. doi: 10.1016/j.atherosclerosis.2008.09.032
   PubMed Web of Science ®Google Scholar
• Devarajan S, Yahiro E, Uehara Y, et al. Depressor effect of chymase inhibitor in mice with high salt-induced moderate hypertension. Am J Physiol Heart Circ Physiol. 2015 Dec 1;309(11):H1987–96. doi: 10.1152/ajpheart.00721.2014
   PubMed Web of Science ®Google Scholar
• Palaniyandi SS, Nagai Y, Watanabe K, et al. Chymase inhibition reduces the progression to heart failure after autoimmune myocarditis in rats. Exp Biol Med (Maywood). 2007 Oct;232(9):1213–1221. doi: 10.3181/0703-RM-85
   PubMed Web of Science ®Google Scholar
• Takai S, Jin D, Chen H, et al. Chymase inhibition improves vascular dysfunction and survival in stroke-prone spontaneously hypertensive rats. J Hypertens. 2014 Aug;32(8):1637–1648. discussion 1649. doi: 10.1097/HJH.0000000000000231
   PubMed Web of Science ®Google Scholar
• Kakimoto K, Takai S, Murano M, et al. Significance of chymase-dependent matrix metalloproteinase-9 activation on indomethacin-induced small intestinal damages in rats. J Pharmacol Exp Ther. 2010 Feb;332(2):684–689. doi: 10.1124/jpet.109.162933
   PubMed Web of Science ®Google Scholar
• Imai Y, Takai S, Jin D, et al. Chymase inhibition attenuates lipopolysaccharide/d-galactosamine-induced acute liver failure in hamsters. Pharmacology. 2014;93(1–2):47–56. doi: 10.1159/000357684
   PubMed Web of Science ®Google Scholar
• Komeda K, Takai S, Jin D, et al. Chymase inhibition attenuates tetrachloride-induced liver fibrosis in hamsters. Hepatol Res. 2010 Aug;40(8):832–840. doi: 10.1111/j.1872-034X.2010.00672.x
   PubMed Web of Science ®Google Scholar
• Tsunemi K, Takai S, Nishimoto M, et al. A specific chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[[3,4-dioxo-1-phenyl-7-(2-pyridyloxy)]-2-heptyl]acetamide (NK3201), suppresses development of abdominal aortic aneurysm in hamsters. J Pharmacol Exp Ther. 2004 Jun;309(3):879–883. doi: 10.1124/jpet.103.063974
   PubMed Web of Science ®Google Scholar
• Takai S, Jin D, Ohzu M, et al. Chymase inhibition provides pancreatic islet protection in hamsters with streptozotocin-induced diabetes. J Pharmacol Sci. 2009 Aug;110(4):459–465. doi: 10.1254/jphs.09115FP
   PubMed Web of Science ®Google Scholar
• Maeda Y, Inoguchi T, Takei R, et al. Chymase inhibition prevents myocardial fibrosis through the attenuation of NOX4-associated oxidative stress in diabetic hamsters. J Diabetes Investig. 2012 Aug 20;3(4):354–361. doi: 10.1111/j.2040-1124.2012.00202.x
   PubMed Web of Science ®Google Scholar
• Maeda Y, Inoguchi T, Takei R, et al. Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters. Am J Physiol Renal Physiol. 2010 Dec;299(6):F1328–38. doi: 10.1152/ajprenal.00337.2010
   PubMed Web of Science ®Google Scholar
• Kosanovic D, Luitel H, Dahal BK, et al. Chymase: a multifunctional player in pulmonary hypertension associated with lung fibrosis. Eur Respir J. 2015 Oct;46(4):1084–1094. doi: 10.1183/09031936.00018215
   PubMed Web of Science ®Google Scholar
• Wang T, Han SX, Zhang SF, et al. Role of chymase in cigarette smoke-induced pulmonary artery remodeling and pulmonary hypertension in hamsters. Respir Res. 2010 Mar 31;11(1):36. doi: 10.1186/1465-9921-11-36
   PubMedGoogle Scholar
• Jin D, Takai S, Yamada M, et al. Impact of chymase inhibitor on cardiac function and survival after myocardial infarction. Cardiovasc Res. 2003 Nov 1;60(2):413–420. doi: 10.1016/S0008-6363(03)00535-2
   PubMed Web of Science ®Google Scholar
• Jin D, Takai S, Yamada M, et al. Beneficial effects of cardiac chymase inhibition during the acute phase of myocardial infarction. Life Sci. 2002 Jun 14;71(4):437–446. doi: 10.1016/S0024-3205(02)01689-2
   PubMed Web of Science ®Google Scholar
• Hoshino F, Urata H, Inoue Y, et al. Chymase inhibitor improves survival in hamsters with myocardial infarction. J Cardiovasc Pharmacol. 2003.Jan;41 Suppl 1:S11–8.
   PubMed Web of Science ®Google Scholar
• Fan YY, Nishiyama A, Fujisawa Y, et al. Contribution of chymase-dependent angiotensin II formation to the progression of tubulointerstitial fibrosis in obstructed kidneys in hamsters. J Pharmacol Sci. 2009 Sep;111(1):82–90. doi: 10.1254/jphs.09152FP
   PubMed Web of Science ®Google Scholar
• Uehara Y, Urata H, Ideishi M, et al. Chymase inhibition suppresses high-cholesterol diet-induced lipid accumulation in the hamster aorta. Cardiovasc Res. 2002 Sep;55(4):870–876. doi: 10.1016/S0008-6363(02)00458-3
   PubMed Web of Science ®Google Scholar
• Hooshdaran B, Kolpakov MA, Guo X, et al. Dual inhibition of cathepsin G and chymase reduces myocyte death and improves cardiac remodeling after myocardial ischemia reperfusion injury. Basic Res Cardiol. 2017 Sep 14;112(6):62. doi: 10.1007/s00395-017-0652-z
   PubMed Web of Science ®Google Scholar
• Oyamada S, Bianchi C, Takai S, et al. Chymase inhibition reduces infarction and matrix metalloproteinase-9 activation and attenuates inflammation and fibrosis after acute myocardial ischemia/reperfusion. J Pharmacol Exp Ther. 2011 Oct;339(1):143–151. doi: 10.1124/jpet.111.179697
   PubMed Web of Science ®Google Scholar
• Zheng J, Wei CC, Hase N, et al. Chymase mediates injury and mitochondrial damage in cardiomyocytes during acute ischemia/reperfusion in the dog. PLoS One. 2014;9(4):e94732. doi: 10.1371/journal.pone.0094732
   PubMed Web of Science ®Google Scholar
• Duengen HD, Kim RJ, Zahger D, et al. 87 effects of the chymase inhibitor fulacimstat on adverse cardiac remodelling after acute myocardial infarction - results of the CHIARA MIA 2 trial. Eur Heart J. 2019;40(Supplement_1). doi:10.1093/eurheartj/ehz747.0017
   Google Scholar
• Duengen HD, Kim RJ, Zahger D, et al. Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction-results of the chymase inhibitor in adverse remodeling after myocardial infarction (CHIARA MIA) 2 trial. Am Heart J. 2020 Jun;224:129–137.
   PubMed Web of Science ®Google Scholar
• Okamura K, Kuroda R, Nagata K, et al. Prospective single-arm observational study of human chymase inhibitor Polygonum hydropiper L in subjects with hypertension. Clin Exp Hypertens. 2019;41(8):717–725. doi: 10.1080/10641963.2018.1545847
   PubMed Web of Science ®Google Scholar
• Takai S, Jin D, Nishimoto M, et al. Oral administration of a specific chymase inhibitor, NK3201, inhibits vascular proliferation in grafted vein. Life Sci. 2001;69(15):1725–1732. doi: 10.1016/S0024-3205(01)01255-3
   PubMed Web of Science ®Google Scholar
• Takai S, Jin D, Sakaguchi M, et al. An orally active chymase inhibitor, BCEAB, suppresses heart chymase activity in the hamster. Jpn J Pharmacol. 2001;86(1):124–126. doi: 10.1254/jjp.86.124
   PubMedGoogle Scholar
• Wei CC, Hase N, Inoue Y, et al. Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J Clin Invest. 2010 Apr;120(4):1229–1239. doi: 10.1172/JCI39345
   PubMed Web of Science ®Google Scholar
• Kanemitsu H, Takai S, Tsuneyoshi H, et al. Chymase inhibition prevents cardiac fibrosis and dysfunction after myocardial infarction in rats. Hypertens Res. 2006 Jan;29(1):57–64. doi: 10.1291/hypres.29.57
   PubMed Web of Science ®Google Scholar
• Jin D, Takai S, Nonaka Y, et al. A chymase Inhibitory RNA aptamer improves cardiac function and survival after myocardial infarction. Mol Ther Nucleic Acids. 2019 Mar 1;14:41–51. doi: 10.1016/j.omtn.2018.11.001
   PubMedGoogle Scholar
• Houde M, Schwertani A, Touil H, et al. Mouse mast cell protease 4 deletion protects heart function and survival after Permanent myocardial infarction. Front Pharmacol. 2018;9:868. DOI:10.3389/fphar.2018.00868
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu CL, Fang W, et al. Deficiency of mouse mast cell protease 4 mitigates cardiac dysfunctions in mice after myocardium infarction. Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1170–1181. doi: 10.1016/j.bbadis.2019.01.011
   PubMed Web of Science ®Google Scholar
• Tejada T, Tan L, Torres RA, et al. IGF-1 degradation by mouse mast cell protease 4 promotes cell death and adverse cardiac remodeling days after a myocardial infarction. Proc Natl Acad Sci U S A. 2016 Jun 21;113(25):6949–6954. doi: 10.1073/pnas.1603127113
   PubMed Web of Science ®Google Scholar
• Butts B, Ahmed MI, Bajaj NS, et al. Reduced left atrial emptying fraction and chymase activation in pathophysiology of primary mitral regurgitation. JACC Basic Transl Sci. 2020 Feb;5(2):109–122. doi: 10.1016/j.jacbts.2019.11.006
   PubMedGoogle Scholar
• Butts B, Goeddel LA, Zheng J, et al. Impact of early pericardial fluid chymase activation after cardiac surgery. Front Cardiovasc Med. 2023;10:1132786. Epub 20230412. doi: 10.3389/fcvm.2023.1132786
   PubMed Web of Science ®Google Scholar
• Okamura K, Okuda T, Shirai K, et al. Positive correlation between blood pressure or heart rate and chymase-dependent angiotensin II-forming activity in circulating mononuclear leukocytes measured by new ELISA. Clin Exp Hypertens. 2018;40(2):112–117. doi: 10.1080/10641963.2017.1339071
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Wada A, Tsutamoto T, et al. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation. 2003 May 27;107(20):2555–2558. doi: 10.1161/01.CIR.0000074041.81728.79
   PubMed Web of Science ®Google Scholar
• Pat B, Chen Y, Killingsworth C, et al. Chymase inhibition prevents fibronectin and myofibrillar loss and improves cardiomyocyte function and LV torsion angle in dogs with isolated mitral regurgitation. Circulation. 2010 Oct 12;122(15):1488–1495. doi: 10.1161/CIRCULATIONAHA.109.921619
   PubMed Web of Science ®Google Scholar
• Takato H, Yasui M, Ichikawa Y, et al. The specific chymase inhibitor TY-51469 suppresses the accumulation of neutrophils in the lung and reduces silica-induced pulmonary fibrosis in mice. Exp Lung Res. 2011 Mar;37(2):101–108. doi: 10.3109/01902148.2010.520815
   PubMed Web of Science ®Google Scholar
• Tomimori Y, Muto T, Saito K, et al. Involvement of mast cell chymase in bleomycin-induced pulmonary fibrosis in mice. Eur J Pharmacol. 2003 Oct 8;478(2–3):179–185. doi: 10.1016/j.ejphar.2003.08.050
   PubMed Web of Science ®Google Scholar
• Coppini R, Santini L, Palandri C, et al. Pharmacological inhibition of serine proteases to reduce cardiac inflammation and fibrosis in atrial fibrillation. Front Pharmacol. 2019;10:1420. DOI:10.3389/fphar.2019.01420
   PubMed Web of Science ®Google Scholar
• Wang H, Varagic J, Nagata S, et al. Atrial angiotensin-(1-12)/chymase expression data in patient of heart diseases. Data Brief. 2020 Aug;31:105744.
   PubMed Web of Science ®Google Scholar
• Powell PC, Wei CC, Fu L, et al. Chymase uptake by cardiomyocytes results in myosin degradation in cardiac volume overload. Heliyon. 2019 Apr;5(4):e01397. doi: 10.1016/j.heliyon.2019.e01397
   PubMed Web of Science ®Google Scholar
• Wang H, Varagic J, Nagata S, et al. Differential expression of the angiotensin-(1-12)/Chymase axis in human atrial tissue. J Surg Res. 2020 Sep;253:173–184.
   PubMed Web of Science ®Google Scholar
• Okamura K, Kuroda R, Nagata K, et al. Prospective single-arm observational study of human chymase inhibitor Polygonum hydropiper L in subjects with hypertension. Ann Clin Exp Hypertens. 2019;41(8):717–725. 2019/11/17. doi: 10.1080/10641963.2018.1545847
   Google Scholar
• Ansary TM, Urushihara M, Fujisawa Y, et al. Effects of the selective chymase inhibitor TEI-F00806 on the intrarenal renin-angiotensin system in salt-treated angiotensin I-infused hypertensive mice. Exp Physiol. 2018 Nov;103(11):1524–1531. doi: 10.1113/EP087209
   PubMed Web of Science ®Google Scholar
• Bivona BJ, Takai S, Seth DM, et al. Chymase inhibition retards albuminuria in type 2 diabetes. Physiol Rep. 2019 Dec;7(24):e14302. doi: 10.14814/phy2.14302
   PubMed Web of Science ®Google Scholar
• Rossing P, Strand J, Avogaro A, et al. Effects of the chymase inhibitor fulacimstat in diabetic kidney disease—results from the CADA DIA trial. Nephrol Dialysis Transplantation. 2020;36(12):2263–2273. doi: 10.1093/ndt/gfaa299
   Web of Science ®Google Scholar
• Huang XR, Chen WY, Truong LD, et al. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol. 2003 Jul;14(7):1738–1747. doi: 10.1097/01.ASN.0000071512.93927.4E
   PubMed Web of Science ®Google Scholar
• Cristovam PC, Arnoni CP, de Andrade MC, et al. ACE-dependent and chymase-dependent angiotensin II generation in normal and glucose-stimulated human mesangial cells. Exp Biol Med (Maywood). 2008 Aug;233(8):1035–1043. doi: 10.3181/0708-RM-229
   PubMed Web of Science ®Google Scholar
• McPherson EA, Luo Z, Brown RA, et al. Chymase-like angiotensin II-generating activity in end-stage human autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2004 Feb;15(2):493–500. doi: 10.1097/01.ASN.0000109782.28991.26
   PubMed Web of Science ®Google Scholar
• de Garavilla L, Greco MN, Sukumar N, et al. A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti-inflammatory activity in vivo. J Biol Chem. 2005 May 6;280(18):18001–18007. doi: 10.1074/jbc.M501302200
   PubMed Web of Science ®Google Scholar
• Dungen HD, Kober L, Nodari S, et al. Safety and Tolerability of the chymase inhibitor Fulacimstat in patients with left ventricular dysfunction after myocardial infarction-results of the CHIARA MIA 1 trial. Clin Pharmacol Drug Dev. 2019 Oct;8(7):942–951. doi: 10.1002/cpdd.633
   PubMed Web of Science ®Google Scholar
• Zhang M, Huang W, Bai J, et al. Chymase inhibition protects diabetic rats from renal lesions. Mol Med Rep. 2016 Jul;14(1):121–128. doi: 10.3892/mmr.2016.5234
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim JW, Ko NY, et al. Mast cell-mediated allergic response is suppressed by sophorae flos: inhibition of SRC-family kinase. Exp Biol Med (Maywood). 2008 Oct;233(10):1271–1279. doi: 10.3181/0803-RM-89
   PubMed Web of Science ®Google Scholar
• Dispenza MC. The use of Bruton’s tyrosine kinase inhibitors to treat allergic disorders. Curr Treat Options Allergy. 2021;8(3):261–273. doi: 10.1007/s40521-021-00286-y
   PubMedGoogle Scholar
• Louis RE, Radermecker MF. Substance P-induced histamine release from human basophils, skin and lung fragments: effect of nedocromil sodium and theophylline. Int Arch Allergy Appl Immunol. 1990;92(4):329–333. doi: 10.1159/000235160
   PubMedGoogle Scholar
• Wei L, Wang J, Zhang X, et al. Discovery of 2H-Chromen-2-one derivatives as G protein-coupled receptor-35 agonists. J Med Chem. 2017 Jan 12;60(1):362–372. doi: 10.1021/acs.jmedchem.6b01431
   PubMed Web of Science ®Google Scholar
• Theoharides TC. Potential association of mast cells with coronavirus disease 2019. Ann Allergy Asthma Immunol. 2021 Mar;126(3):217–218. doi: 10.1016/j.anai.2020.11.003
   PubMed Web of Science ®Google Scholar